Article

The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma.

Haematologica (Impact Factor: 5.87). 01/2006; 90(12):1713-4.
Source: PubMed

ABSTRACT Multiple myeloma (MM) is a clonal neoplastic lymphoproliferative disease affecting terminally differentiated B cells i.e. plasma cells characterized by slow proliferation activity and different resistance to apoptosis with latent accumulation of myeloma cells in the bone marrow. This process is induced by failure of normal tissue homeostatic mechanisms. We compared plasma cell proliferation and apoptic indices in various phases of MM and in monoclonal gammophaty of untetermined significance.

Download full-text

Full-text

Available from: Jiri Minarik, Aug 17, 2015
0 Followers
 · 
77 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess the outcome of the measurement of apoptotic index in myeloma patients treated by conventional chemotherapy and novel drugs with biological mechanism of action, thalidomide and bortezomib. In a cohort of 189 patients with newly diagnosed multiple myeloma from November 1997 through February 2008, we assessed the prognostic significance of plasma cell apoptotic index (PC-AI) using annexin-V. The whole group was subsequently divided according to treatment approach (conventional chemotherapy only vs. inclusion of novel drugs, thalidomide and bortezomib), and curves of overall survival were constructed. In the whole group (n = 189), low levels of PC-AI <4.5% significantly separated patients with unfavorable prognosis (median OS 16 vs. 38 months, P = 0.004). In patients treated with conventional chemotherapy only (n = 139) the results were similar (median OS 10 vs. 25 months, P = 0.02), and the apoptotic index maintained its significance even within the group of 50 patients treated also with novel drugs (median OS 30 vs. 54 months, P = 0.027). PC-AI was found to be independent on both Durie-Salmon staging system and the International Prognostic Index. Presented results suggest the use of apoptotic index by flow cytometry measurement as a fast and accessible method for prognostic stratification of myeloma patients in routine practice.
    European Journal Of Haematology 08/2009; 83(6):528-34. DOI:10.1111/j.1600-0609.2009.01321.x · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a group of 310 patients with multiple myeloma (MM) we assessed the proliferative (PC-PI) and apoptotic indices (PC-AI). Patients were divided according to the disease state, i.e. at the time of diagnosis, in relapse, and in MM remission. We assessed the behavior of both indices with respect to therapy response and activity of the disease. In patients who reached remission, there was a significant decrease of PC-PI together with an increase of PC-AI in comparison with initial measurements. In non-responders, there was a reverse trend with increasing PC-PI and decreasing PC-AI. The values of PC-PI and PC-AI in residual myeloma population were similar regardless of treatment, i.e. in patients treated using conventional chemotherapy and after high-dosed chemotherapy with autologous stem cell transplant. Patients in long-lasting remission phase maintained stable low values of PC-PI with high PC-AI without a significant change, whereas in the group of progressing/relapsing patients, there was a significant increase of PC-PI together with a decrease of PC-AI. Our results suggest that longitudinal measurement of proliferative and apoptotic indices in MM plasmocytes helps to estimate the behavior of the tumor population and may thus become a convenient auxiliary parameter for prognosis and a targeted, individualized treatment approach.
    Leukemia & lymphoma 10/2009; 50(12):1983-91. DOI:10.3109/10428190903291070 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We assessed plasma cell proliferation (by propidium iodide index, PC-PI) and apoptosis (by annexin-V index PC-AI) for the estimation of overall survival (OS) in multiple myeloma (MM) patients. 181 patients with newly diagnosed MM were assessed, treated using conventional chemotherapy. The values best discriminating patients with poor prognosis were PC-PI>3.0% and PC-AI<4.75%, and for good prognosis PC-PI≤3.0% and PC-AI≥4.75%. The median OS was 8 months vs 40 months, p=0.0002. Our results suggest that combined measurement of plasma cell proliferation and apoptosis creates a unique strong prognostic factor based on growth characteristics of the tumor clone.
    Leukemia research 01/2011; 35(1):44-8. DOI:10.1016/j.leukres.2010.04.015 · 2.69 Impact Factor
Show more